01. Innovations and models of financing to improving diagnostic services under the East Africa Laboratory Project

Thursday, 30 October 2014, 17:00 - 18:30
Room 111

Sponsored Satellite Symposium

Track
Tuberculosis

Topic
Public policy

Organised by
East, Central and Southern Africa Health Community

Description
This session will share an innovative conceptual framework developed for assessing the economic and health impact of investing laboratories; share lessons learnt from implementation of performance-based financing in accelerating laboratory quality improvement; present options for promoting public-private partners; and highlight results from the introduction of new technologies in improving diagnostic services and opportunities in public-private partnerships to support laboratory services delivery in the region.

Target audience
Infectious disease experts, senior MOH officials, TB programme managers, key policy-makers, development partners, and representatives of civil society organisations.

Objectives
1. Share conceptual framework for assessing the economic and health impact of investing in laboratories
2. Present results from the application of performance-based financing related to laboratories
3. Explore potential public-private partnerships in support of laboratory service delivery in the region
4. Discuss impact of new technologies in resource-constrained settings in cross border areas

Keywords
Tuberculosis

Coordinator(s)
Martin Matu (Tanzania, United Rep.)

Chair(s)
Miriam Schneidman (USA)

Presentations
17:00 - 17:15 Overview of the EAPHLNP
   Miriam Schneidman (USA)
17:15 - 17:30 Conceptual framework for evaluating economic and health impact of investing in laboratories
   Anna Krivelyova (USA)
17:30 - 17:45 Experiences on implementation of performance-based financing to accelerate laboratory accreditation
   Claver Kayobotsi (Rwanda)
17:45 - 18:00 Early lessons derived from a study to explore the impact of new diagnostics in TB diagnosis
   Willie Githui (Kenya)
18:00 - 18:15 Opportunities for public-private partnerships in supporting laboratory service delivery in the region
   Martin Matu (Tanzania, United Rep.)
18:15 - 18:30 Discussion
# 02. Expansion of M/XDR-TB programmatic management in the Russian Federation

**Thursday, 30 October 2014, 17:00 - 18:30**

**Room 113**

## Sponsorship
- Type: Sponsored Satellite Symposium
- Track: Tuberculosis
- Topic: Medical management of TB and drug resistant TB

## Organizers
- Regional public organization for the disabled people (RPODP) “Human Health”, Russia

## Description
For the past few years the Russian Federation has been demonstrating significant decreasing of TB notification and TB mortality rates. However, increasing rates of M/XDR-TB is a remaining challenge for TB control in the country. The overall aim of the programme is to present modern approaches to TB control and national best practices focused on effective M/XDR-TB management.

## Target Audience
- NTP managers, TB consultants, TB specialists, TB laboratory specialists.

## Objectives
1. To share experiences and best practices of M/XDR-TB management in a MDR-TB high-burden country
2. To discuss challenges and opportunities for improvement of M/XDR-TB management in the Russian Federation.

## Keywords
- Tuberculosis; MDR-TB; XDR-TB; PMDT; TB laboratory diagnosis

## Coordinator(s)
- Vadim Testov (Russian Federation)

## Chair(s)
- Irina Vasilyeva (Russian Federation), Teresa Kasaeva (Russian Federation)

## Presentations

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>17:00 - 17:15</td>
<td>M/XDR-TB: the challenges for TB control in the Russian Federation</td>
<td>Irina Vasilyeva (Russian Federation)</td>
</tr>
<tr>
<td>17:15 - 17:30</td>
<td>Diaskin-test: new variation of TB skin test</td>
<td>Ludmila Slogotskaya (Russian Federation)</td>
</tr>
<tr>
<td>17:30 - 17:45</td>
<td>New national laboratory algorithm for TB detection, diagnostic and DST</td>
<td>Larisa Chernousova (Russian Federation)</td>
</tr>
<tr>
<td>17:45 - 18:00</td>
<td>MDR-TB treatment outcomes in the Russian Federation</td>
<td>Vadim Testov (Russian Federation)</td>
</tr>
<tr>
<td>18:00 - 18:15</td>
<td>Treatment of M/XDR-TB: challenges and new opportunities</td>
<td>Anastasia Samoilova (Russian Federation)</td>
</tr>
<tr>
<td>18:15 - 18:30</td>
<td>MSF activities for PMDT implementation in the North Caucasus, Russia Federation (example of collaboration)</td>
<td>Animesh Sinha (Netherlands)</td>
</tr>
</tbody>
</table>
**03. Streamlining treatment for drug-resistant TB: market approaches for better TB care**

**Thursday, 30 October 2014, 17:00 - 18:30**

**Room 114**

<table>
<thead>
<tr>
<th>Type</th>
<th>Sponsored Satellite Symposium</th>
</tr>
</thead>
<tbody>
<tr>
<td>Track</td>
<td>Tuberculosis</td>
</tr>
<tr>
<td>Topic</td>
<td>Medical management of TB and drug resistant TB</td>
</tr>
<tr>
<td>Organised by</td>
<td>UNITAID</td>
</tr>
</tbody>
</table>

**Description**

A wide range of treatment options exist with the use of around 20 drug-resistant TB medicines. While some variation is vital, other options may be clinically unnecessary. This complicates TB care and fragments an already small market, leading to supply shortages and high prices. Simpler, shorter TB treatment could foster healthier markets, better enabling appropriate TB medicines to be provided to people who urgently need them. But evidence is needed to inform effective use of new and existing medicines. This session will explore market trends and potential impact of streamlining drug-resistant TB treatment.

**Target audience**

Many stakeholders have an interest in understanding needs and likely evolution of TB medicines markets, including implementers, governments, donors, international organisations, regulators, policy-makers, civil society, academics, and industry.

**Objectives**

1. Review the urgent need for shorter, safer, effective drug-resistant TB treatment
2. Examine the TB landscape to understand the potential impact of streamlined treatment
3. Describe tangible first steps in transforming markets for drug-resistant TB treatment
4. Discuss further strategies to improve drug-resistant TB care through market approaches

**Keywords**

Access; MDR-TB; medicines; innovation; markets; tuberculosis

**Coordinator(s)**

Janet Ginnard (Switzerland), Katherine Blumer (Switzerland)

**Chair(s)**

Brenda Waning (Switzerland), Carol Nawina Nyirenda (Zambia)

**Presentations**

<table>
<thead>
<tr>
<th>Time</th>
<th>Presentation</th>
</tr>
</thead>
</table>
| 17:00 - 17:15| Perspectives from the community: the need for shorter, safer effective drug-resistant TB treatment  
Dolene Von Delft (South Africa), Thato Mosidi (South Africa) |
| 17:20 - 17:35| Insights from the TB medicines landscape: pre-conditions for new drugs impact  
Carmen Perez Casas (Switzerland) |
| 17:40 - 17:55| Priority drug-resistant TB regimens: improving the knowledge base to transform the market  
Michael Rich (USA) |
| 18:00 - 18:15| Further strategies to consolidate demand: addressing non-essential variation and other opportunities  
Regina Osih (South Africa) |
| 18:20 - 18:30| Discussion                                                                  |
05. Implementing innovation: MDR-TB advancements for adults and children

Thursday, 30 October 2014, 17:00 - 18:30

Room 116

Type: Sponsored Satellite Symposium
Track: Tuberculosis
Topic: Medical management of TB and drug resistant TB
Organised by: Otsuka SA

Description:
The symposium will focus on advancements in clinical research for MDR-TB in adults and children and profile the Young Innovator in TB Research Award winner. Questions to be addressed: following regulatory approval of two new MDR-TB medicines, what can be done to ensure responsible access? What are the challenges of conducting MDR-TB trials in children? Prof. Wiel de Lange, University Medical Center Groningen, will provide an overview of the MDR-TB drug development landscape. Dr Lawrence Geiter, Otsuka, will provide an update on delamanid clinical development, including safety/efficacy data for XDR-TB. Dr Melchor Frias, De La Salle Health Sciences Institute, will present new research on dosing for paediatric MDR-TB patients. Dr Francis Drobniewski, Imperial College London, will conclude with how these new tools can be successfully implemented in a programmatic context.

Target audience:
Scientists, researchers, public health representatives, advocates and others involved in TB care and control

Objectives:
1. Present progress on the development and implementation of new anti-TB compounds
2. Share the latest available clinical data on delamanid research and impact on XDR-TB sub-populations
3. Provide an overview of the challenges and progress in facilitating clinical trials for MDR-TB in children

Keywords: MDR-TB; trials; children

Coordinator(s): Marc Destito (Switzerland)
Chair(s): Wiel De Lange (Netherlands)

Presentations:
17:00 - 17:10 Welcome and introduction
   Wiel De Lange (Netherlands)
17:10 - 17:35 Delamanid for multidrug-resistant tuberculosis (MDR-TB)
   Lawrence Geiter (USA)
17:35 - 17:55 Conducting early drug development trials in children with MDR-TB
   Melchor Frias (Philippines)
17:55 - 18:15 Two new TB drugs: what more do we need?
   Francis Drobniewski (UK)
18:15 - 18:30 Refreshments and discussion with Global Winner of 2014 Young Innovator in TB Research Award
Current health challenges can only be overcome when a wide array of stakeholders work together to conduct operational research that illuminates effective solutions. But this also requires an understanding of operational research concepts and techniques. Because stakeholders frequently lack the time and resources needed to attend traditional face-to-face courses, TREAT TB has developed an approach to web-based learning that provides stakeholders with the knowledge and training they need to conduct high-quality and programmatically-relevant operational research.

Policy-makers, health professionals, government officials, major donors and others interested in operational research.

1. Demonstrate how new technology can bring high-quality operational research training to health professionals
2. Explain how complex technical subjects can be mastered using interactive software.

TB; operational research; global health.

Tara Ornstein (USA)
Ya Diul Mukadi (USA), Lynne Franco [USA]

17:00 - 17:15 Virtual OR Training: early experiences within the TREAT TB Initiative
I. D. Rusen (Canada)

17:15 - 17:30 Pulmonary TB contact tracing in a priority municipality for disease control in Brazil
Anneliese Wysocki (Brazil)

17:30 - 17:45 Which combination of the six tuberculosis screening questions predicts sputum smear which highest accuracy
Stephen Kisorio (Kenya)

17:45 - 18:00 Early anti-retroviral therapy initiation of MDR-TB and HIV co-infected patients in Swaziland
Janet Ongole (Swaziland)

18:00 - 18:15 Factors associated with unsuccessful treatment outcomes of MDR-TB patients in Tamil Nadu state, India
Sree T. Sucharitha (India)

18:15 - 18:30 Discussion
07. The paediatric TB drug market: progress and future direction

Friday, 31 October 2014, 17:00 - 18:30
Room 116

Type: Sponsored Satellite Symposium
Track: Adult and Child Lung Health
Topic: TB in children and LTBI treatment
Organised by: TB Alliance and UNITAID

Description: Paediatric TB is one of the top causes of death in children worldwide. The lack of appropriate medicine has contributed to this problem, however the market for paediatric TB medicines is finally changing, with important recent progress. This session presents new data to clarify the size and dynamics of the paediatric TB drug market; provides updates on progress to bring new, child-friendly formulations of both existing and new drugs to the field; and offers perspectives on how to maximise uptake, improving children’s access to appropriate, affordable, quality TB medicine.

Target audience: NTP managers, health programme managers and policy-makers, specialists and agencies providing technical assistance, manufacturers, donors, paediatricians.

Objectives:
1. Present new market research data to clarify the volume and dynamics of the current paediatric treatment market
2. Provide update on progress of current efforts to make paediatric drugs in the correct dosages
3. Discuss strategies to ensure maximum uptake of new paediatric treatments coming to market
4. Offer overview of new treatments in development and their potential impact

Keywords: Paediatric TB; market dynamics; formulations; dosage; product introduction; policies; clinical trials

Coordinator(s): Joanna Breitstein (USA), Janet Ginnard (Switzerland)
Chair(s): Phillipe Duneton (Switzerland), Clemax Sant Anna (Brazil)

Presentations:
17:00 - 17:10 Market understanding: new data on the purchasing habits of 22 high-burden countries
Cherise Scott (USA)
17:15 - 17:25 Progress and challenges in optimising and delivering new paediatric products
Vijay Agarwal (India)
17:30 - 17:40 Finding the most neglected: identifying and treating more children with TB
Dyah Mustikawati (Indonesia)
17:45 - 17:55 Strategies to promote uptake of appropriately formulated paediatric TB drugs
Malgorzata Grzemska (Switzerland)
18:00 - 18:10 Tomorrow’s treatments: outlook for the paediatric TB drug pipeline
Anneke Hesseling (South Africa)
18:15 - 18:30 Discussion
In October 2012, the Ethiopian government with key national and international partners launched a multiyear initiative to build sustainable capacity for operational research (OR) funded under the USAID TB CARE I initiative with the aim to develop strong technical capacity at national and regional levels to enhance the use of TB research for evidence based TB control. Using a “learning by doing approach” and a local mentorship programme, new capacity was built and existing capacity enhanced. During this symposium the OR initiative and results of OR projects conducted will be presented focusing on the impact on TB control and how to keep building sustainable OR capacity.

### Target audience
TB researchers, policy-makers and representative of national TB programmes who like to learn how operational research capacity can successfully be built.

### Objectives
1. To share experience on sustainable operational research capacity can be built
2. To share result of OR projects conducted under the Ethiopian OR initiative and their implications for TB control
3. To discuss best practices and way forward in building sustainable operational research capacity that is used to improve programme performance

### Keywords
Operational research

### Coordinator(s)
Dawit Assefa Lemma (Ethiopia), Eveline Klinkenberg (Ethiopia)

### Chair(s)
Biruck Negash (Ethiopia), Abraham Aseffa (Ethiopia)

### Presentations

<table>
<thead>
<tr>
<th>Time</th>
<th>Presentation</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>17:00 - 17:10</td>
<td>Overview of the Ethiopia OR initiative</td>
<td>Ezra Shimeles (Ethiopia)</td>
</tr>
<tr>
<td>17:10 - 17:20</td>
<td>Centralised versus decentralised tuberculosis care: the case of Oromia Region, Ethiopia</td>
<td>Kassa Hailu (Ethiopia)</td>
</tr>
<tr>
<td>17:20 - 17:30</td>
<td>A quarter of health centers had poor symptomatic tuberculosis screening practice in Amhara region, Ethiopia</td>
<td>Gebremedhin Gebregergs (Ethiopia)</td>
</tr>
<tr>
<td>17:30 - 17:40</td>
<td>Opportunities and challenges in the management of MDR-TB patients in the treatment follow-up centers in Addis Ababa</td>
<td>Daniel Fiseha Adhana (Ethiopia)</td>
</tr>
<tr>
<td>17:40 - 17:50</td>
<td>Factors associated with case notification of smear-positive TB in Southern Nation, nationalities and People Region</td>
<td>Tarekegn Solomon (Ethiopia)</td>
</tr>
<tr>
<td>17:50 - 18:00</td>
<td>Building sustainable capacity for operational research, lessons learned and the way forward</td>
<td>Eveline Klinkenberg (Ethiopia)</td>
</tr>
<tr>
<td>18:00 - 18:30</td>
<td>Roundtable discussing the best ways to build OR capacity</td>
<td></td>
</tr>
</tbody>
</table>
09. Responding to MDR-TB from the ground up: case studies on community-driven solutions

Friday, 31 October 2014, 17:00 - 18:30
Room 120/121

Sponsored Satellite Symposium

Tuberculosis

Medical management of TB and drug resistant TB

The Lilly MDR-TB Partnership

This session showcases creative, effective and low-cost solutions to improving MDR-TB treatment outcomes. Experience shows supporting people on treatment at the one-on-one level improves treatment success rates. This session highlights models that can be easily replicated: collaborating with religious groups and traditional medicine in China; building pharmacist and rural healthcare provider capacity as community support in India; developing a sustainable approach for groups at greatest risk of loss to follow-up in Russia; strengthening the support web by partnering with government in South Africa; and tipping the scales on treatment outcomes through small investments in social support.

This session is targeted to a broad audience interested in MDR-TB. This may include civil society organisations, advocates, policy-makers, national TB programme staff, researchers, donors, health care professionals, national and international partners.

Objectives
1. To illustrate concrete examples of models which address MDR-TB in a variety of community-based settings
2. To share implementation of lessons learnt
3. To enhance MDR-TB care and outcomes through community-based approaches

Keywords
- MDR-TB

Coordinator(s)
Amy Israel (Switzerland)

Chair(s)
Evan Lee (Switzerland), Eliud Wandwalo (Switzerland)

Presentations

17:00 - 17:05 Welcome
Evan Lee (Switzerland)

17:05 - 17:10 Setting the stage: the need for community-based solutions in addressing MDR-TB
Eliud Wandwalo (Switzerland)

17:10 - 17:20 Strengthening community engagement: working with religious groups, media and traditional medicine in China
Yong Cheng Ma (China)

17:20 - 17:30 Tapping into a cadre of community based pharmacists and rural healthcare providers to tip the scales in India
Vikas Panibatla (India)

17:30 - 17:40 Replicating the Sputnik model to reach groups at greatest risk in Russia
Salmaan Keshavjee (USA)

17:40 - 17:50 Connecting community with follow up in the Eastern Cape, South Africa: clinics, homes, schools and prisons
Mike Brunt (South Africa)

17:50 - 18.00 Improving adherence one individual at a time: lessons from the Red Cross approach
Lasha Goguadze (Switzerland)

18:00 - 18:30 Panel discussion